<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Carcinoma of the penis: Clinical presentation, diagnosis, and staging</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Carcinoma of the penis: Clinical presentation, diagnosis, and staging</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Carcinoma of the penis: Clinical presentation, diagnosis, and staging</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Curtis A Pettaway, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerome P Richie, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 17, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H282022432"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Carcinoma of the penis is rare in the United States, Europe, and other industrialized countries. However, the incidence of these malignancies is much higher in parts of South America, Africa, and Asia.</p><p>The clinical presentation, diagnosis, and staging of penile cancer are reviewed here. Related topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3002.html" rel="external">"Carcinoma of the penis: Epidemiology, risk factors, and pathology"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16866.html" rel="external">"Carcinoma of the penis: Surgical and medical treatment"</a>.)</p><p></p><p class="headingAnchor" id="H282022439"><span class="h1">ANATOMY OF THE PENIS AND REGIONAL NODES</span><span class="headingEndMark"> — </span>The anatomic components of the penis include the following  (<a class="graphic graphic_figure graphicRef76391" href="/z/d/graphic/76391.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Penile shaft</strong> – The penile shaft consists of the skin, subepithelial connective tissue, the erectile bodies (ie, corpora cavernosum), and the urethra, which is surrounded by the corpora spongiosum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Penile glans</strong> – The penile glans (ie, head of the penis) consists of an epithelial covering and the underlying dermis but is largely made up of a "spongy" expansion of the corpora spongiosum. At the tip of the glans is the urethral meatus, which allows for urination and ejection of semen. The proximal rounded surface of the glans penis is called the corona and serves as the junction between the glans and the penile shaft.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Foreskin</strong> – The foreskin is an extension of the shaft skin, which covers the glans penis at birth. Circumcision is a procedure that removes the foreskin at birth or later in life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regional lymphatics</strong> – Penile lymphatics drain both the glans penis and shaft and form an interconnecting network of channels. Drainage proceeds from the superficial inguinal lymph nodes to the deep inguinal lymph nodes and then to the external iliac lymph nodes in the pelvis.</p><p></p><p class="headingAnchor" id="H282022446"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Penile carcinoma almost always presents with a skin abnormality or palpable lesion on the penis. The majority of cancers arise on the glans, in the coronal sulcus, or on the prepuce as either a mass or ulceration, and they may be associated with a secondary infection. In a series of 243 males with newly diagnosed penile cancer, the most common signs were a painless lump (25 percent) or ulcer (13 percent) [<a href="#rid1">1</a>]. Other signs included a rash (6 percent), bleeding (4 percent), or balanitis (4 percent).</p><p>Penile cancer is typically a disease of older males, and rates increase steadily with age [<a href="#rid2">2,3</a>]. The mean age at diagnosis is 60 years, although penile cancer can be seen in males less than 40 years old [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/3002.html" rel="external">"Carcinoma of the penis: Epidemiology, risk factors, and pathology", section on 'Epidemiology'</a>.)</p><p>Inguinal adenopathy is present in 30 to 60 percent of cases at diagnosis, although malignant infiltration of the lymph nodes is demonstrated in only approximately one-half of these cases. Lymphadenopathy in the remainder presumably represents an inflammatory reaction [<a href="#rid6">6</a>].</p><p>Distant metastases are uncommon until late in the disease course, with only 1 to 10 percent of cases having distant metastases at presentation [<a href="#rid7">7-12</a>]. (See <a class="local">'TNM staging evaluation'</a> below.)</p><p class="headingAnchor" id="H7028347"><span class="h1">INITIAL EVALUATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of penile carcinoma should be suspected in males who present with a penile mass or ulcer, particularly in those who have not been circumcised. The diagnosis requires biopsy for tissue confirmation. (See  <a class="medical medical_review" href="/z/d/html/3002.html" rel="external">"Carcinoma of the penis: Epidemiology, risk factors, and pathology", section on 'Pathology'</a>.)</p><p>The initial evaluation of a penile mass or ulcer depends upon whether the clinical presentation suggests that infection or malignancy is more likely:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suspected infection</strong> – If an infection appears to be more likely (eg, erythema, swelling, discharge), a four- to six-week course of antifungals or antibiotics may be indicated, depending on the clinical exam. The use of steroids is reserved for patients with a biopsy-confirmed diagnosis of an inflammatory lesion (ie, lichen sclerosus). Lesions that do not resolve after six weeks or that progress at any time during antibiotic or antifungal therapy should be biopsied. (See  <a class="medical medical_review" href="/z/d/html/6876.html" rel="external">"Balanitis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suspected malignancy</strong> – For males presenting with a penile lesion suspicious for malignancy or with a penile lesion and associated lymphadenopathy, our approach is to proceed with an immediate biopsy of the penile lesion. If this is positive, evaluation of the regional lymph nodes is indicated. (See <a class="local">'Regional lymph node assessment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other signs or symptoms</strong> – The presence of other physical signs (eg, firm subcutaneous skin nodules at distant sites) or symptoms (eg, cachexia, confusion, cough, or bone pain) may indicate the presence of distant metastatic disease or associated metabolic abnormalities, such as hypercalcemia. Such patients require a full laboratory and imaging evaluation in addition to biopsy. (See <a class="local">'Assessment for distant metastatic disease'</a> below.)</p><p></p><p>Biopsy can be performed using punch, incisional, or excisional techniques [<a href="#rid13">13</a>]. Excisional biopsy is appropriate when the complete lesion can be removed and closed with little or no alteration to penile form and function. Otherwise, incisional or deep punch biopsies are performed.</p><p>All patients require close follow-up to prevent an unnecessary delay in diagnosis and treatment.</p><p class="headingAnchor" id="H1191415403"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The definitive diagnosis of penile malignancy is based upon the biopsy of the penile lesion. An incisional or deep punch biopsy is preferred because it provides the most information to guide subsequent staging and treatment.</p><p class="headingAnchor" id="H2550255145"><span class="h2">Malignant lesions</span><span class="headingEndMark"> — </span>Approximately 95 percent of malignant lesions of the penis are squamous cell carcinoma. A number of other rare malignancies can also arise in the penis. (See  <a class="medical medical_review" href="/z/d/html/3002.html" rel="external">"Carcinoma of the penis: Epidemiology, risk factors, and pathology", section on 'Other malignancies'</a>.)</p><p>Squamous cell carcinoma must be distinguished from other malignancies that may present with penile lesions, as well as from premalignant and nonmalignant lesions. (See  <a class="medical medical_review" href="/z/d/html/3002.html" rel="external">"Carcinoma of the penis: Epidemiology, risk factors, and pathology", section on 'Pathology'</a>.)</p><p class="headingAnchor" id="H282022488"><span class="h2">Inflammatory conditions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genital psoriasis</strong> – Psoriasis involves the genital area in 40 percent of affected individuals [<a href="#rid14">14</a>]. The plaques are erythematous, with sharply defined margins that are raised above the surrounding normal skin. Typical psoriatic scales may not be present due to the moisture in the genital area. These lesions are usually asymptomatic, although some patients complain of pruritus. Psoriasis is rarely limited to the penis, and the presence of psoriatic scales elsewhere helps distinguish psoriasis from penile cancer. (See  <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angiokeratomas </strong>– Angiokeratomas are uncommon, benign, violaceous papules with overlying scale  (<a class="graphic graphic_picture graphicRef95066" href="/z/d/graphic/95066.html" rel="external">picture 1</a>). Penile angiokeratomas often occur on the glans penis but can be found on the scrotum, thigh, and elsewhere. Typically, they are multiple and measure less than 1 cm in diameter [<a href="#rid15">15</a>]. The small size and multiplicity are useful in distinguishing angiokeratomas from penile cancer, which is more commonly a single, larger lesion. In most patients, the lesions are asymptomatic and do not require treatment; however, intermittent bleeding, pruritus, and pain can occur.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen planus</strong> – Lichen planus involving the penis is characterized by violaceous papules on the glans  (<a class="graphic graphic_picture graphicRef53806 graphicRef76913" href="/z/d/graphic/53806.html" rel="external">picture 2A-B</a>). Unlike penile cancer, lichen planus lesions are rarely asymptomatic. Most patients experience pruritus, which can be severe and become intensely painful if the lesions ulcerate or erode. The disease usually heals with significant postinflammatory hyperpigmentation. (See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus", section on 'Genital lichen planus'</a>.)</p><p></p><p class="headingAnchor" id="H282022496"><span class="h2">Infectious conditions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genital herpes</strong> – Genital herpes is caused by infection with herpes simplex virus 1 (HSV1) or 2 (HSV2). The initial presentation can be severe, with painful genital ulcers in association with other manifestations, including systemic symptoms (eg, fever, headache, malaise) and tender local inguinal lymphadenopathy. In contrast, cancerous lesions are usually painless and not associated with systemic symptoms. A clinical diagnosis of genital herpes should be confirmed with laboratory testing. (See  <a class="medical medical_review" href="/z/d/html/8347.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary syphilis</strong> – Syphilis is a chronic infection caused by the bacterium <em>Treponema pallidum</em>. Primary syphilis can present with a painless papule on the penis. With time, the papule ulcerates to produce the classic chancre of primary syphilis, a 1 to 2 cm ulcer with a raised, indurated margin. The ulcer generally has a nonexudative base and is associated with mild to moderate regional lymphadenopathy, which is often bilateral. Multiple chancres can occur, particularly in the setting of human immunodeficiency virus (HIV) infection. Unlike penile cancer, chancres heal spontaneously within three to six weeks, even in the absence of treatment. (See  <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Clinical manifestations'</a>.)</p><p></p><p class="headingAnchor" id="H282022525"><span class="h2">Premalignant lesions</span><span class="headingEndMark"> — </span>Several penile lesions are recognized as premalignant and have the capacity to evolve into frankly invasive squamous cell carcinoma. These premalignant lesions are generally differentiated from squamous cell carcinoma by biopsy.</p><p>The extent to which premalignant lesions precede invasive carcinoma is unknown. The available evidence suggests that the majority of cases of penile squamous cell carcinoma arise de novo [<a href="#rid16">16</a>]. As an example, in one series, only 39 of 511 males with penile cancer (8 percent) had a history of a previous or concomitant lesion [<a href="#rid17">17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Condyloma acuminata</strong> – Condyloma acuminata, also known as genital or venereal warts, are soft papillomatous growths that are associated with human papillomavirus (HPV) infection in the anogenital area. Although condylomata generally follow a benign course and are most often associated with low-risk HPV types 6 and 11, malignant transformation has been noted, particularly in association with high-risk HPV subtypes 16, 18, 31, 33, 35, and 39 [<a href="#rid18">18,19</a>].</p><p></p><p class="bulletIndent1">The increased incidence of penile carcinoma in males with condyloma acuminata was illustrated in a population-based case-control study of 110 males with penile cancer and 355 control subjects, in which there was a sixfold increased risk of penile carcinoma in males reporting a history of genital warts compared with those without such a history [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/3002.html" rel="external">"Carcinoma of the penis: Epidemiology, risk factors, and pathology", section on 'HPV'</a> and  <a class="medical medical_review" href="/z/d/html/99981.html" rel="external">"Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical premalignant penile lesions pathologically defined as PeIN </strong>– The following clinically defined entities are pathologically designated as Penile Intraepithelial Neoplasia (PeIN). PeIN is further stratified by the presence or absence of HPV infection (HPV associated or HPV independent) [<a href="#rid21">21</a>]. These entities were previously pathologically classified as "carcinoma in situ".</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Erythroplasia of Queyrat</strong> – Erythroplasia of Queyrat is a clinical entity used to describe PeIN arising within the penile mucocutaneous epithelium, namely the glans and prepuce  (<a class="graphic graphic_picture graphicRef66886" href="/z/d/graphic/66886.html" rel="external">picture 3</a>). It has a typical velvety red, well-marginated appearance. The lesions are usually solitary and occasionally erode or ulcerate, but pain is uncommon. In this regard, they may appear quite similar to penile carcinoma.</p><p></p><p class="bulletIndent2">PeIN in this location usually affects older, uncircumcised males. The reported incidence of progression to invasive carcinoma ranges from 10 to 33 percent [<a href="#rid22">22-25</a>]. The development of ulceration and/or a papillary appearance is associated with disease progression [<a href="#rid23">23</a>]. In such lesions, a coinfection with HPV types 8 and 16 has been described, and such lesions would be pathologically classified as HPV-associated PeIN [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bowen disease</strong> – Bowen disease is a PeIN occurring within follicle-bearing epithelium, such as on the penile shaft  (<a class="graphic graphic_picture graphicRef61920" href="/z/d/graphic/61920.html" rel="external">picture 4</a>). It usually appears as a solitary, dull-red plaque with areas of crusting and oozing [<a href="#rid22">22</a>]. In one series, HPV-16 was present in four of five biopsy specimens of genital PeIN occurring in this location, which are pathologically classified as HPV-associated PeIN [<a href="#rid26">26</a>]. If left untreated, invasive squamous cell carcinoma develops in approximately 5 percent of cases [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bowenoid papulosis</strong> – Bowenoid papulosis is another lesion that histologically resembles PeIN. This form of PeIN is most often seen in younger males. It usually behaves in a benign fashion and rarely becomes invasive [<a href="#rid25">25</a>]. It is characterized by multiple slightly elevated papules that are red to violet in color, which distinguish this entity from penile carcinoma  (<a class="graphic graphic_picture graphicRef76025" href="/z/d/graphic/76025.html" rel="external">picture 5</a>). Lesions usually form on the penile shaft, although the glans and prepuce may also be affected [<a href="#rid27">27,28</a>]. HPV-16 has been implicated in the pathogenesis of this form of PeIN, so such lesions would be pathologically classified as HPV-associated PeIN [<a href="#rid29">29-32</a>].</p><p></p><p class="bulletIndent2">While the clinical course of typical Bowenoid papulosis occurring in young males is usually benign [<a href="#rid33">33</a>], the disease has been shown to progress to invasive squamous cell carcinoma in some reports [<a href="#rid30">30,31</a>]. Advanced age and immunosuppression may enhance the risk of malignant progression [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen sclerosus (also known as balanitis xerotica obliterans)</strong> – Lichen sclerosus is characterized by white atrophic plaques on the glans and prepuce  (<a class="graphic graphic_picture graphicRef78530" href="/z/d/graphic/78530.html" rel="external">picture 6</a>). These plaques eventually enlarge and coalesce into a sclerotic mass with resultant adhesions, phimosis, and meatal stenosis. Although many of the cases appear in males who have not undergone neonatal circumcision [<a href="#rid35">35,36</a>], this is not always the case [<a href="#rid37">37,38</a>]. (See  <a class="medical medical_review" href="/z/d/html/6876.html" rel="external">"Balanitis in adults"</a>.)</p><p></p><p class="bulletIndent1">Although generally considered benign, there is a relationship between lichen sclerosus and squamous cell carcinoma in that the two may coexist or lichen sclerosus may precede the later development of penile cancer:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a series of 130 males with genital lichen sclerosus, 11 had malignant or premalignant features (8.5 percent), including squamous cell carcinoma in seven, verrucous carcinoma in two, squamous cell carcinoma associated with verrucous carcinoma in one, and erythroplasia of Queyrat in one [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another report of 86 males with genital lichen sclerosus, premalignant or malignant histologic features developed in five cases, four of whom were HPV positive. The average lag time from onset of lichen sclerosus to the development of penile cancer was 17 years (range 10 to 23 years) [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukoplakia</strong> – Chronic irritation and/or inflammation are thought to be important in the pathogenesis of leukoplakia, a rare condition that typically presents as solitary or multiple, white, scaly plaques often involving the meatus. Although the exact relationship to penile carcinoma is unknown, leukoplakia is often found adjacent or contiguous to areas of squamous cell carcinoma. The premalignant nature of leukoplakia is suggested by the presence of dysplasia in 10 to 20 percent of cases [<a href="#rid22">22,28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous horn</strong> – The penile cutaneous horn is a rare lesion. It usually develops over a preexisting skin lesion (wart, nevus, traumatic abrasion, or malignant neoplasm) and is characterized by overgrowth and cornification of the epithelium, which forms a solid protuberance  (<a class="graphic graphic_picture graphicRef112579" href="/z/d/graphic/112579.html" rel="external">picture 7</a>) [<a href="#rid40">40</a>]. In one review, cutaneous horn was also associated with HPV-16, and 37 percent of such lesions were noted to have an underlying carcinoma [<a href="#rid41">41</a>]. Malignant degeneration has been noted in cases of recurrent disease [<a href="#rid42">42</a>]. Penile cutaneous horns may form as a result of or evolve into invasive carcinoma [<a href="#rid43">43,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pseudoepitheliomatous keratotic and micaceous balanitis (PKMB)</strong> – PKMB is an uncommon lesion that is named for its clinical appearance as a hyperkeratotic, laminated, solitary plaque on the glans [<a href="#rid45">45</a>]. PKMB often occurs in older males who are circumcised later in life. While the exact cause of PKMB remains unknown, malignant transformation into verrucous carcinoma has been reported [<a href="#rid46">46-48</a>]. The hallmark of transformation is the development of a nodular exophytic lesion within the preexisting plaque. A biopsy is required to make this diagnosis and to rule out malignant transformation.</p><p></p><p class="headingAnchor" id="H1510254073"><span class="h1">TNM STAGING EVALUATION</span><span class="headingEndMark"> — </span>The eighth edition of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) tumor, node, metastasis (TNM) staging system is used for staging carcinoma of the penis  (<a class="graphic graphic_table graphicRef110727" href="/z/d/graphic/110727.html" rel="external">table 1</a>). The TNM information is used to define prognostic stage groups and to establish the appropriate treatment plan. (See  <a class="medical medical_review" href="/z/d/html/16866.html" rel="external">"Carcinoma of the penis: Surgical and medical treatment"</a>.)</p><p>The TNM staging system is supported by both the AJCC and the Union for International Cancer Control (UICC) [<a href="#rid49">49</a>]. The eighth edition changes included the following [<a href="#rid49">49</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The International Society of Urologic Pathology (ISUP) Grading System [<a href="#rid50">50</a>] was adopted. Any proportion of anaplastic cells is sufficient to categorize a tumor as grade 3.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ta definition was broadened to include noninvasive localized-squamous carcinoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence or absence of perineural invasion was added as another factor to separate T1a from T1b category tumors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The anatomic layers of the penis are now described for the three penile locations, including the glans, foreskin, and shaft.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>T2 definition now includes corpus spongiosum invasion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>T3 definition now includes corpora cavernosum invasion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>pN1 is now defined as ≤2 unilateral inguinal metastases, no extranodal extension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>pN2 is now defined as ≥3 unilateral inguinal metastases or bilateral metastases.</p><p></p><p>The improved prognostic value of the eighth edition TNM penile cancer staging system compared with the prior seventh edition was shown using a multi-institutional data set including patients from both China and the United States [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H764505512"><span class="h2">Tumor assessment</span><span class="headingEndMark"> — </span>Clinical examination by visual inspection and palpation is required to evaluate the primary lesion. When the depth or extent of tumor infiltration cannot be determined by clinical exam, magnetic resonance imaging (MRI) may help identify invasion into the corpora cavernosum or spongiosum [<a href="#rid52">52</a>]. The extent of the primary tumor is combined with the pathologic factors present in the tumor, such as histologic grade, the status of lymphovascular invasion, and perineural invasion, for staging and treatment planning. Thus, an adequate deep tumor biopsy is important to capture this information.</p><p class="headingAnchor" id="H370431933"><span class="h2">Regional lymph node assessment</span><span class="headingEndMark"> — </span>Penile cancer initially spreads through the lymphatics, with the initial site of involvement being the inguinal nodes, followed sequentially by the pelvic and retroperitoneal nodes. Accurate assessment of regional lymph nodes is essential for proper management since resection of small-volume, pathologically involved regional lymph nodes can be curative [<a href="#rid53">53</a>]. </p><p>For clinical staging, factors determining nodal stage include the location, size, and number of any palpable lymph nodes and whether or not such lymph nodes are fixed or mobile. Pathologic staging factors include the number of involved nodes and whether or not extranodal extension or pelvic lymph node metastases are present.</p><p>The presence or absence of lymph node involvement also provides important prognostic information. The single most important prognostic factors influencing survival in patients with penile cancer are the presence and extent of nodal metastases. In a review of the literature, the five-year cancer-specific survival stratified by the extent of nodal involvement was [<a href="#rid54">54</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>No inguinal node metastases – 85 to 100 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Single inguinal lymph node metastasis – 79 to 89 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral or multiple inguinal node metastases – 17 to 60 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Pelvic node metastases – 0 to 17 percent</p><p></p><p class="headingAnchor" id="H3209131654"><span class="h2">Staging techniques</span></p><p class="headingAnchor" id="H1590121850"><span class="h3">Imaging studies</span><span class="headingEndMark"> — </span>For males with a high body mass index (BMI), those who have had prior inguinal procedures, and those presenting with clinical adenopathy, we perform cross-sectional staging imaging studies along with physical examination to assess for regional lymphadenopathy and distant metastases. </p><p class="bulletIndent2"><span class="glyph">•</span>Options for chest imaging include chest radiograph (CXR) or contrast-enhanced computed tomography (CT) of the chest. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Options for abdominal imaging include contrast-enhanced CT abdomen and pelvis or gadolinium-enhanced MRI of the abdomen and pelvis. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with clinically positive inguinal nodes, fluorodeoxyglucose (FDG) positron emission tomography (PET)-CT may be helpful to evaluate for pelvic and distant metastases [<a href="#rid55">55</a>].</p><p></p><p>The rationale for the use of staging imaging studies is because clinical assessment of inguinal lymph nodes is not entirely reliable, and physical examination alone has limited accuracy in these settings [<a href="#rid56">56</a>]. A false-negative clinical evaluation of the inguinal region based upon palpation alone has been reported in 9 to 60 percent of patients, depending on pathologic features of the primary tumor [<a href="#rid57">57,58</a>]. False-positive assessments are also frequent.</p><p class="headingAnchor" id="H1531919736"><span class="h3">Pathologic staging of inguinal lymph nodes</span><span class="headingEndMark"> — </span>Pathologic staging of inguinal lymph nodes is required for patients with palpable lymphadenopathy and for those with no palpable adenopathy at high risk for metastases based upon pathologic features noted in the primary tumor. (See <a class="local">'Staging approach'</a> below.)</p><p class="headingAnchor" id="H4061181167"><span class="h4">Fine needle aspiration</span><span class="headingEndMark"> — </span>Fine needle aspiration (FNA) is a minimally invasive method to evaluate for malignancy in males with penile cancer who present with palpable adenopathy. It is performed without local anesthesia using a 23- to 27-gauge needle. Both the sensitivity and specificity of FNA among males with clinically palpable nodes are over 90 percent [<a href="#rid59">59</a>]. (See <a class="local">'Clinically suspicious inguinal examination'</a> below.)</p><p>FNA alone is not used for routine staging of males without clinically palpable adenopathy, as its sensitivity is much lower in this population. However, it may be performed prior to planned dynamic sentinel node biopsy (DSNB) to increase the sensitivity of detecting tumors [<a href="#rid60">60,61</a>]. As an example, in one such study, the sensitivity of ultrasound-guided FNA was 39 percent (9 of 23 groins containing metastases), with a specificity of 100 percent [<a href="#rid60">60</a>]. (See <a class="local">'Clinically negative inguinal examination'</a> below.)</p><p class="headingAnchor" id="H57524445"><span class="h4">Dynamic sentinel node biopsy (DSNB)</span><span class="headingEndMark"> — </span>Lymphatic mapping and sentinel node biopsy are based upon the concept that penile cancers have specific patterns of lymphatic spread and that one or more lymph nodes (ie, sentinel nodes) are the first to be involved with metastatic disease within a given lymph node basin.</p><p>Dynamic sentinel node biopsy (DSNB) utilizes the injection of the penile tumor with vital blue dye and radioactive tracer, followed by examination of the draining inguinal lymph nodes. If the sentinel lymph nodes are not involved, the entire basin should be free of tumor.</p><p>A 2012 meta-analysis of 17 studies reported on the detection rate and sensitivity of sentinel node biopsy in penile cancer [<a href="#rid62">62</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The pooled sensitivity was 88 percent (95% CI 83-92).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When studies that included patients with palpable nodes were excluded, the pooled sensitivity increased to 90 percent (95% CI 85-94).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Incorporation of inguinal ultrasound increased the pooled sensitivity of sentinel node biopsy to 93 percent.</p><p></p><p>Sentinel lymph node biopsy should be performed at centers staffed by experienced surgeons and nuclear medicine specialists to decrease the risk of a false-negative result. This recommendation is consistent with the National Comprehensive Cancer Network (NCCN) guidelines for penile cancer [<a href="#rid63">63</a>]. The importance of experience was demonstrated in a 2010 study that included 342 patients assessed with a modified DSNB protocol from two high-volume centers [<a href="#rid64">64</a>]. In this experience, the false-negative rate was 2 percent (six patients with groin metastases after a negative DSNB). However, in another center, the false-negative rate approached 15 percent while the technique was evolving [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H1750078116"><span class="h4">Superficial inguinal lymph node dissection (ILND)</span><span class="headingEndMark"> — </span>A superficial inguinal lymph node dissection (ILND) provides more information than biopsy of a single node or group of nodes. This dissection can be readily performed by a surgeon experienced in inguinal surgery, without the need for specialized equipment. For ILND, both laparoscopic and robotic approaches are also safe to stage the inguinal region if performed by an experienced surgeon, as both approaches have low recurrence and complication rates. ILND also requires intraoperative frozen sections of lymph nodes to aid in treatment planning. </p><p>Superficial ILND can identify microscopic metastases in patients with a clinically normal inguinal examination without the need for a pelvic dissection. This was demonstrated in a retrospective study of 31 males, most of whom had nonpalpable inguinal nodes at presentation [<a href="#rid66">66</a>]. There were no recurrences among males who underwent a superficial ILND [<a href="#rid66">66</a>]. However, superficial ILND was associated with a higher overall complication rate compared with DSNB (12 to 35 versus 5 to 14 percent, respectively) [<a href="#rid67">67,68</a>]. </p><p>One study has shown that superficial ILND can be performed using a minimally invasive robotic-assisted approach, with similar lymph node yields compared with open surgical approaches [<a href="#rid69">69</a>]. Similarly, laparoscopic surgical resection techniques have been described that appear to be feasible as staging procedures. If performed by an experienced surgeon, these procedures can be used to stage patients with clinically negative nodes, as they have both low recurrence and complication rates [<a href="#rid69">69-72</a>]. Based on clinical guidelines from the American Society of Clinical Oncology and the European Association of Urology (ASCO-EAU), both laparoscopic and robotic approaches are acceptable techniques to stage the inguinal region among patients with no clinically palpable or visibly enlarged inguinal lymph nodes (cN0) who are being treated at centers with management expertise in penile cancer [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H152489881"><span class="h2">Staging approach</span><span class="headingEndMark"> — </span>The optimal approach to staging the inguinal lymph nodes is based on the probability of lymph node involvement based upon tumor stage and other histologic features. This enables the selection of patients at high risk for nodal involvement who are most likely to benefit from surgical staging.</p><p class="headingAnchor" id="H4061722634"><span class="h3">Clinically negative inguinal examination</span><span class="headingEndMark"> — </span>For males with a clinically negative inguinal examination, the extent of staging is based upon the risk of occult nodal metastases.</p><p>Our approach is consistent with guidelines from the ASCO-EAU and the NCCN guidelines for staging of males with newly diagnosed penile cancer  (<a class="graphic graphic_algorithm graphicRef114727" href="/z/d/graphic/114727.html" rel="external">algorithm 1</a>) [<a href="#rid63">63</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-risk disease</strong> – For males with low-risk disease (pTis [PeIN], Ta, or T1a  (<a class="graphic graphic_table graphicRef110727" href="/z/d/graphic/110727.html" rel="external">table 1</a>)), we offer surveillance. However, patients must agree to be compliant with follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-risk disease</strong> – For males with high-risk disease (≥pT1b), DSNB is the preferred technique in experienced centers based on lower complication rates. When DSNB is not available or feasible, ILND via either an open, laparoscopic, or robotic approach is an appropriate alternative, depending upon local expertise patient preference. CT/MRI or inguinal ultrasound may be useful in planning surgical staging. Surveillance is not recommended for this patient cohort.</p><p></p><p class="headingAnchor" id="H2971471151"><span class="h3">Clinically suspicious inguinal examination</span><span class="headingEndMark"> — </span>For males with evidence of palpable adenopathy on clinical examination, we offer FNA for pathologic assessment. The FNA is sensitive and reliable enough for diagnostic purposes in this population and, thus, can aid in further treatment planning  (<a class="graphic graphic_algorithm graphicRef114728" href="/z/d/graphic/114728.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef114729" href="/z/d/graphic/114729.html" rel="external">algorithm 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>For males with low-risk disease (pTis [PeIN], pTa, pT1a  (<a class="graphic graphic_table graphicRef110727" href="/z/d/graphic/110727.html" rel="external">table 1</a>)) with clinically suspicious adenopathy but a negative FNA, we perform an excisional biopsy for definitive evaluation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For males with high-risk disease (≥T1b) with clinically suspicious adenopathy but a negative FNA, we perform a superficial ILND with frozen section evaluation of the nodes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For males with a positive FNA, we proceed with definitive surgical treatment. (See  <a class="medical medical_review" href="/z/d/html/16866.html" rel="external">"Carcinoma of the penis: Surgical and medical treatment"</a>.)</p><p></p><p>For patients with proven metastases by FNA or node biopsy, additional imaging studies, such as CT and PET-CT, may be of value in predicting adverse nodal features, such as ≥3 positive nodes, extranodal extension, or pelvic metastases [<a href="#rid55">55,73</a>].</p><p class="headingAnchor" id="H538865875"><span class="h3">Bulky inguinal nodes, pelvic nodes, or unresectable lymphadenopathy</span><span class="headingEndMark"> — </span>Males with penile cancer who present with bulky, fixed inguinal nodes (size ≥4 cm), pelvic lymph nodes, or unresectable lymphadenopathy have relatively low survival rates when treated with surgery alone. Such patients are candidates for multimodality therapy, such as neoadjuvant chemotherapy or chemoradiation [<a href="#rid74">74-76</a>]. Biopsy confirmation with assessment for metastatic disease is recommended prior to treatment. (See  <a class="medical medical_review" href="/z/d/html/16866.html" rel="external">"Carcinoma of the penis: Surgical and medical treatment", section on 'Neoadjuvant chemotherapy for locally advanced or unresectable disease'</a>.)</p><p class="headingAnchor" id="H2336719302"><span class="h2">Assessment for distant metastatic disease</span><span class="headingEndMark"> — </span>Distant disease dissemination is rare until late in the disease course, and penile cancer rarely presents with distant metastases. Therefore, we do not perform routine diagnostic imaging to assess for distant metastatic disease unless the patient exhibits regional nodal metastases. As an example, in one series of 681 patients, only 24 (4 percent) developed distant metastatic disease and, in all cases, it was late in the course following locoregional treatment [<a href="#rid77">77</a>].</p><p>For patients with bulky regional nodal metastases and those presenting with signs and symptoms of metastatic disease (eg, cachexia, pain, cough, skin lesions away from the primary site), CT of the chest, abdomen, and pelvis should be performed. PET/CT is also a sensitive imaging option that should be considered [<a href="#rid55">55,73</a>]. In addition, routine laboratory studies should include serum calcium to evaluate for tumor-induced hypercalcemia because prompt treatment can rapidly reverse altered mental status [<a href="#rid78">78</a>]. Brain metastasis from penile carcinoma is exceedingly rare, and MRI of the brain for asymptomatic patients is not indicated.</p><p class="headingAnchor" id="H282022638"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The definitive diagnosis of penile cancer requires histopathologic examination of a biopsy specimen. (See <a class="local">'Initial evaluation and diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/3002.html" rel="external">"Carcinoma of the penis: Epidemiology, risk factors, and pathology", section on 'Pathology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of a patient presenting with a penile lesion includes infectious, inflammatory, premalignant, and malignant etiologies. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suspected</strong> <strong>infection</strong> – For males with penile lesions that are more likely to be infectious (eg, erythema, swelling, discharge) and are not associated with inguinal lymphadenopathy, a course of antifungals or antibiotics may be indicated. Lesions that do not resolve after six weeks or that progress at any time should be biopsied. (See <a class="local">'Initial evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suspected malignancy</strong> – For males presenting with a penile lesion suspicious for malignancy or with a penile lesion and associated lymphadenopathy, our approach is to proceed with an immediate biopsy of the penile lesion. (See <a class="local">'Initial evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anatomy</strong> <strong>of the penis and regional nodes</strong> – Penile cancer initially spreads through the lymphatics, with the initial site of involvement being the inguinal nodes, followed sequentially by the pelvic and retroperitoneal nodes. Accurate assessment of regional lymph nodes is essential for proper management. (See <a class="local">'Regional lymph node assessment'</a> above and <a class="local">'Anatomy of the penis and regional nodes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging imaging studies</strong> – For males with a high body mass index (BMI), those with prior inguinal procedures, and those presenting with clinical adenopathy, we perform cross-sectional staging imaging studies of the chest, abdomen, and pelvis along with physical examination. (See <a class="local">'Imaging studies'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Options for chest imaging include chest radiograph (CXR) or contrast-enhanced computed tomography (CT) of the chest. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Options for abdominal imaging include contrast-enhanced CT abdomen and pelvis or gadolinium-enhanced magnetic resonance imaging (MRI) of the abdomen and pelvis. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with clinically positive inguinal nodes, fluorodeoxyglucose (FDG) positron emission tomography (PET)-CT may be helpful to evaluate for pelvic and distant metastases. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic staging of regional lymph nodes</strong> – The optimal approach to pathologic staging of the inguinal lymph nodes is based on the presence or absence of clinically palpable inguinal lymph nodes and the probability of lymph node involvement based upon tumor stage and other histologic features. (See <a class="local">'Staging approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No clinically palpable inguinal lymph nodes (cN0)</strong> – For males with no palpable inguinal adenopathy on clinical examination (cN0)  (<a class="graphic graphic_algorithm graphicRef114727" href="/z/d/graphic/114727.html" rel="external">algorithm 1</a>) (see <a class="local">'Clinically negative inguinal examination'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Low-risk disease</strong> – For males with low-risk disease (pTis [PeIN], Ta, or T1a  (<a class="graphic graphic_table graphicRef110727" href="/z/d/graphic/110727.html" rel="external">table 1</a>)), we offer surveillance. However, patients must agree to be compliant with follow-up. (See  <a class="medical medical_review" href="/z/d/html/16866.html" rel="external">"Carcinoma of the penis: Surgical and medical treatment", section on 'Treatment of low-risk disease'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>High-risk disease</strong> – For males with high-risk disease (≥pT1b), we offer dynamic sentinel node biopsy (DSNB) in experienced centers based on lower complication rates. When DSNB is not available or feasible, superficial inguinal lymph node dissection (ILND) via an open, laparoscopic, or robotic approach is an appropriate alternative, depending upon local expertise and patient preferences. CT/MRI or inguinal ultrasound may be useful in planning surgical staging. Surveillance is not recommended for this patient cohort.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinically palpable inguinal lymph nodes</strong> – For males with palpable inguinal adenopathy on clinical exam, we offer fine needle aspiration (FNA) for pathologic assessment.  (<a class="graphic graphic_algorithm graphicRef114728" href="/z/d/graphic/114728.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef114729" href="/z/d/graphic/114729.html" rel="external">algorithm 3</a>) (See <a class="local">'Clinically suspicious inguinal examination'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For males with low-risk disease with clinically suspicious adenopathy but a negative FNA, we perform an excisional biopsy for definitive diagnosis.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For males with high-risk disease with clinically suspicious adenopathy but a negative FNA, we perform a superficial ILND with frozen section evaluation of lymph nodes.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For males with a positive FNA, we proceed with definitive surgical treatment. (See  <a class="medical medical_review" href="/z/d/html/16866.html" rel="external">"Carcinoma of the penis: Surgical and medical treatment"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bulky inguinal nodes, pelvic nodes, or unresectable lymphadenopathy</strong> – For males who present with bulky (node ≥4 cm) or fixed inguinal nodes, pelvic lymph nodes, or unresectable lymphadenopathy, further staging workup to define the extent of disease is indicated prior to therapy. (See <a class="local">'Bulky inguinal nodes, pelvic nodes, or unresectable lymphadenopathy'</a> above and  <a class="medical medical_review" href="/z/d/html/16866.html" rel="external">"Carcinoma of the penis: Surgical and medical treatment", section on 'Neoadjuvant chemotherapy for locally advanced or unresectable disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment for distant metastases</strong> – Distant metastases are rare until late in the disease course, and penile cancer rarely presents with disseminated disease. Laboratory and imaging workup should be guided by physical signs or symptoms. (See <a class="local">'Assessment for distant metastatic disease'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ritchie AW, Foster PW, Fowler S, BAUS Section of Oncology. Penile cancer in the UK: clinical presentation and outcome in 1998/99. BJU Int 2004; 94:1248.</a></li><li><a class="nounderline abstract_t">Goodman MT, Hernandez BY, Shvetsov YB. Demographic and pathologic differences in the incidence of invasive penile cancer in the United States, 1995-2003. Cancer Epidemiol Biomarkers Prev 2007; 16:1833.</a></li><li><a class="nounderline abstract_t">Hernandez BY, Barnholtz-Sloan J, German RR, et al. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer 2008; 113:2883.</a></li><li><a class="nounderline abstract_t">Hegarty PK, Kayes O, Freeman A, et al. A prospective study of 100 cases of penile cancer managed according to European Association of Urology guidelines. BJU Int 2006; 98:526.</a></li><li><a class="nounderline abstract_t">Favorito LA, Nardi AC, Ronalsa M, et al. Epidemiologic study on penile cancer in Brazil. Int Braz J Urol 2008; 34:587.</a></li><li><a class="nounderline abstract_t">Heyns CF, Mendoza-Valdés A, Pompeo AC. Diagnosis and staging of penile cancer. Urology 2010; 76:S15.</a></li><li><a class="nounderline abstract_t">BEGGS JH, SPRATT JS Jr. EPIDERMOID CARCINOMA OF THE PENIS. J Urol 1964; 91:166.</a></li><li><a class="nounderline abstract_t">STAUBITZ WJ, LENT MH, OBERKIRCHER OJ. Carcinoma of the penis. Cancer 1955; 8:371.</a></li><li><a class="nounderline abstract_t">RIVEROS M, GOROSTIAGA R. Cancer of the penis. Arch Surg 1962; 85:377.</a></li><li><a class="nounderline abstract_t">Derrick FC Jr, Lynch KM Jr, Kretkowski RC, Yarbrough WJ. Epidermoid carcinoma of the penis: computer analysis of 87 cases. J Urol 1973; 110:303.</a></li><li><a class="nounderline abstract_t">Johnson DE, Fuerst DE, Ayala AG. Carcinoma of the penis. Experience with 153 cases. Urology 1973; 1:404.</a></li><li><a class="nounderline abstract_t">Kossow JH, Hotchkiss RS, Morales PA. Carcinoma of penis treated surgically. Analysis of 100 cases. Urology 1973; 2:169.</a></li><li class="breakAll">American Joint Committee on Cancer.. Penis.. In: American Joint Committee on Cancer, 7, Edge SB, Byrd DR, Compton CC (Eds), Springer, New York 2010. p.447.</li><li><a class="nounderline abstract_t">Buechner SA. Common skin disorders of the penis. BJU Int 2002; 90:498.</a></li><li><a class="nounderline abstract_t">Leis-Dosil VM, Alijo-Serrano F, Aviles-Izquierdo JA, et al. Angiokeratoma of the glans penis: clinical, histopathological and dermoscopic correlation. Dermatol Online J 2007; 13:19.</a></li><li><a class="nounderline abstract_t">Micali G, Innocenzi D, Nasca MR, et al. Squamous cell carcinoma of the penis. J Am Acad Dermatol 1996; 35:432.</a></li><li><a class="nounderline abstract_t">Jensen MO. Cancer of the penis in Denmark 1942 to 1962 (511 cases). Dan Med Bull 1977; 24:66.</a></li><li><a class="nounderline abstract_t">Boxer RJ, Skinner DG. Condylomata acuminata and squamous cell carcinoma. Urology 1977; 9:72.</a></li><li><a class="nounderline abstract_t">Smotkin D. Virology of human papillomavirus. Clin Obstet Gynecol 1989; 32:117.</a></li><li><a class="nounderline abstract_t">Maden C, Sherman KJ, Beckmann AM, et al. History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 1993; 85:19.</a></li><li><a class="nounderline abstract_t">Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol 2022; 82:458.</a></li><li><a class="nounderline abstract_t">Mikhail GR. Cancers, precancers, and pseudocancers on the male genitalia. A review of clinical appearances, histopathology, and management. J Dermatol Surg Oncol 1980; 6:1027.</a></li><li><a class="nounderline abstract_t">Graham JH, Helwig EB. Erythroplasia of Queyrat. A clinicopathologic and histochemical study. Cancer 1973; 32:1396.</a></li><li><a class="nounderline abstract_t">Wieland U, Jurk S, Weissenborn S, et al. Erythroplasia of queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ. J Invest Dermatol 2000; 115:396.</a></li><li><a class="nounderline abstract_t">Morton CA, Birnie AJ, Eedy DJ. British Association of Dermatologists' guidelines for the management of squamous cell carcinoma in situ (Bowen's disease) 2014. Br J Dermatol 2014; 170:245.</a></li><li><a class="nounderline abstract_t">Ikenberg H, Gissmann L, Gross G, et al. Human papillomavirus type-16-related DNA in genital Bowen's disease and in Bowenoid papulosis. Int J Cancer 1983; 32:563.</a></li><li><a class="nounderline abstract_t">Lucia MS, Miller GJ. Histopathology of malignant lesions of the penis. Urol Clin North Am 1992; 19:227.</a></li><li><a class="nounderline abstract_t">Schellhammer PF, Jordan GH, Robey EL, Spaulding JT. Premalignant lesions and nonsquamous malignancy of the penis and carcinoma of the scrotum. Urol Clin North Am 1992; 19:131.</a></li><li><a class="nounderline abstract_t">Gross G, Hagedorn M, Ikenberg H, et al. Bowenoid papulosis. Presence of human papillomavirus (HPV) structural antigens and of HPV 16-related DNA sequences. Arch Dermatol 1985; 121:858.</a></li><li><a class="nounderline abstract_t">Bonnekoh B, Mahrle G, Steigleder GK. [Transition to cutaneous squamous cell carcinoma in 2 patients with bowenoid papulomatosis]. Z Hautkr 1987; 62:773.</a></li><li><a class="nounderline abstract_t">Yoneta A, Yamashita T, Jin HY, et al. Development of squamous cell carcinoma by two high-risk human papillomaviruses (HPVs), a novel HPV-67 and HPV-31 from bowenoid papulosis. Br J Dermatol 2000; 143:604.</a></li><li><a class="nounderline abstract_t">Endo M, Yamashita T, Jin HY, et al. Detection of human papillomavirus type 16 in bowenoid papulosis and nonbowenoid tissues. Int J Dermatol 2003; 42:474.</a></li><li><a class="nounderline abstract_t">Patterson JW, Kao GF, Graham JH, Helwig EB. Bowenoid papulosis. A clinicopathologic study with ultrastructural observations. Cancer 1986; 57:823.</a></li><li><a class="nounderline abstract_t">Schwartz RA, Janniger CK. Bowenoid papulosis. J Am Acad Dermatol 1991; 24:261.</a></li><li><a class="nounderline abstract_t">Campus GV, Alia F, Bosincu L. Squamous cell carcinoma and lichen sclerosus et atrophicus of the prepuce. Plast Reconstr Surg 1992; 89:962.</a></li><li><a class="nounderline abstract_t">Pride HB, Miller OF 3rd, Tyler WB. Penile squamous cell carcinoma arising from balanitis xerotica obliterans. J Am Acad Dermatol 1993; 29:469.</a></li><li><a class="nounderline abstract_t">Barbagli G, Palminteri E, Mirri F, et al. Penile carcinoma in patients with genital lichen sclerosus: a multicenter survey. J Urol 2006; 175:1359.</a></li><li><a class="nounderline abstract_t">Depasquale I, Park AJ, Bracka A. The treatment of balanitis xerotica obliterans. BJU Int 2000; 86:459.</a></li><li><a class="nounderline abstract_t">Nasca MR, Innocenzi D, Micali G. Penile cancer among patients with genital lichen sclerosus. J Am Acad Dermatol 1999; 41:911.</a></li><li><a class="nounderline abstract_t">Lowe FC, McCullough AR. Cutaneous horns of the penis: an approach to management. Case report and review of the literature. J Am Acad Dermatol 1985; 13:369.</a></li><li><a class="nounderline abstract_t">Solivan GA, Smith KJ, James WD. Cutaneous horn of the penis: its association with squamous cell carcinoma and HPV-16 infection. J Am Acad Dermatol 1990; 23:969.</a></li><li><a class="nounderline abstract_t">Fields T, Drylie D, Wilson J. Malignant evolution of penile horn. Urology 1987; 30:65.</a></li><li><a class="nounderline abstract_t">PRESMAN D, ROLNICK D, TURBOW B. Penile horn. Am J Surg 1962; 104:640.</a></li><li><a class="nounderline abstract_t">Hassan AA, Orteza AM, Milam DF. Penile horn: review of literature with 3 case reports. J Urol 1967; 97:315.</a></li><li><a class="nounderline abstract_t">Bargman H. Pseudoepitheliomatous, keratotic, and micaceous balanitis. Cutis 1985; 35:77.</a></li><li><a class="nounderline abstract_t">Beljaards RC, van Dijk E, Hausman R. Is pseudoepitheliomatous, micaceous and keratotic balanitis synonymous with verrucous carcinoma? Br J Dermatol 1987; 117:641.</a></li><li><a class="nounderline abstract_t">Gray MR, Ansell ID. Pseudo-epitheliomatous hyperkeratotic and micaceous balanitis: evidence for regarding it as pre-malignant. Br J Urol 1990; 66:103.</a></li><li><a class="nounderline abstract_t">Child FJ, Kim BK, Ganesan R, et al. Verrucous carcinoma arising in pseudoepitheliomatous keratotic and micaceous balanitis, without evidence of human papillomavirus. Br J Dermatol 2000; 143:183.</a></li><li class="breakAll">Pettaway CA, Srigley JR, Brookland RK, et al. Penis. In: AJCC Cancer Staging Manual, Eighth, Amin MB (Ed), 2017. p.701.</li><li class="breakAll">Cubilla AL, Ayala A, Ayala G, et al. Malignant epithelial tumours. In: WHO Classification of Tumours of the Urinary System and Male Genital Organs, 8th, Moch H, Humphry PA, Ulbright TN, Reuter VE (Eds), WHO Press, Lyon 2016. Vol 8, p.262.</li><li><a class="nounderline abstract_t">Wang B, Gu W, Wan F, et al. Prognosis of the 8th TNM Staging System for Penile Cancer and Refinement of Prognostication by Incorporating High Risk Human Papillomavirus Status. J Urol 2020; 203:562.</a></li><li><a class="nounderline abstract_t">Petralia G, Villa G, Scardino E, et al. Local staging of penile cancer using magnetic resonance imaging with pharmacologically induced penile erection. Radiol Med 2008; 113:517.</a></li><li><a class="nounderline abstract_t">Marconnet L, Rigaud J, Bouchot O. Long-term followup of penile carcinoma with high risk for lymph node invasion treated with inguinal lymphadenectomy. J Urol 2010; 183:2227.</a></li><li><a class="nounderline abstract_t">Ficarra V, Akduman B, Bouchot O, et al. Prognostic factors in penile cancer. Urology 2010; 76:S66.</a></li><li><a class="nounderline abstract_t">Graafland NM, Leijte JA, Valdés Olmos RA, et al. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. Eur Urol 2009; 56:339.</a></li><li><a class="nounderline abstract_t">Delacroix SE Jr, Pettaway CA. Therapeutic strategies for advanced penile carcinoma. Curr Opin Support Palliat Care 2010; 4:285.</a></li><li><a class="nounderline abstract_t">Sánchez-Ortiz RF, Pettaway CA. The role of lymphadenectomy in penile cancer. Urol Oncol 2004; 22:236.</a></li><li><a class="nounderline abstract_t">Leijte JA, Kirrander P, Antonini N, et al. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 2008; 54:161.</a></li><li><a class="nounderline abstract_t">Saisorn I, Lawrentschuk N, Leewansangtong S, Bolton DM. Fine-needle aspiration cytology predicts inguinal lymph node metastasis without antibiotic pretreatment in penile carcinoma. BJU Int 2006; 97:1225.</a></li><li><a class="nounderline abstract_t">Kroon BK, Horenblas S, Deurloo EE, et al. Ultrasonography-guided fine-needle aspiration cytology before sentinel node biopsy in patients with penile carcinoma. BJU Int 2005; 95:517.</a></li><li><a class="nounderline abstract_t">Lee EWC, Issa A, Oliveira P, et al. High diagnostic accuracy of inguinal ultrasonography and fine-needle aspiration followed by dynamic sentinel lymph node biopsy in men with impalpable and palpable inguinal lymph nodes. BJU Int 2022; 130:331.</a></li><li><a class="nounderline abstract_t">Sadeghi R, Gholami H, Zakavi SR, et al. Accuracy of sentinel lymph node biopsy for inguinal lymph node staging of penile squamous cell carcinoma: systematic review and meta-analysis of the literature. J Urol 2012; 187:25.</a></li><li class="breakAll">NCCN guidelines. https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf (Accessed on March 14, 2020).</li><li><a class="nounderline abstract_t">Graafland NM, Lam W, Leijte JA, et al. Prognostic factors for occult inguinal lymph node involvement in penile carcinoma and assessment of the high-risk EAU subgroup: a two-institution analysis of 342 clinically node-negative patients. Eur Urol 2010; 58:742.</a></li><li><a class="nounderline abstract_t">Kirrander P, Andrén O, Windahl T. Dynamic sentinel node biopsy in penile cancer: initial experiences at a Swedish referral centre. BJU Int 2013; 111:E48.</a></li><li><a class="nounderline abstract_t">Spiess PE, Hernandez MS, Pettaway CA. Contemporary inguinal lymph node dissection: minimizing complications. World J Urol 2009; 27:205.</a></li><li><a class="nounderline abstract_t">Wever L, de Vries HM, Dell'Oglio P, et al. Incidence and risk factor analysis of complications after sentinel node biopsy for penile cancer. BJU Int 2022; 130:486.</a></li><li><a class="nounderline abstract_t">Brouwer OR, Albersen M, Parnham A, et al. European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update. Eur Urol 2023; 83:548.</a></li><li><a class="nounderline abstract_t">Matin SF, Cormier JN, Ward JF, et al. Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU Int 2013; 111:1068.</a></li><li><a class="nounderline abstract_t">Master VA, Jafri SM, Moses KA, et al. Minimally invasive inguinal lymphadenectomy via endoscopic groin dissection: comprehensive assessment of immediate and long-term complications. J Urol 2012; 188:1176.</a></li><li><a class="nounderline abstract_t">Singh A, Jaipuria J, Goel A, et al. Comparing Outcomes of Robotic and Open Inguinal Lymph Node Dissection in Patients with Carcinoma of the Penis. J Urol 2018; 199:1518.</a></li><li><a class="nounderline abstract_t">Kumar V, Sethia KK. Prospective study comparing video-endoscopic radical inguinal lymph node dissection (VEILND) with open radical ILND (OILND) for penile cancer over an 8-year period. BJU Int 2017; 119:530.</a></li><li><a class="nounderline abstract_t">Graafland NM, Teertstra HJ, Besnard AP, et al. Identification of high risk pathological node positive penile carcinoma: value of preoperative computerized tomography imaging. J Urol 2011; 185:881.</a></li><li><a class="nounderline abstract_t">Graafland NM, van Boven HH, van Werkhoven E, et al. Prognostic significance of extranodal extension in patients with pathological node positive penile carcinoma. J Urol 2010; 184:1347.</a></li><li><a class="nounderline abstract_t">Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010; 28:3851.</a></li><li class="breakAll">NCCN Clinical Practice Guidelines in Oncology: Penile Cancer, v3, 2015. http://www.nccn.org/professionals/physician_gls/pdf/penile.pdf (Accessed on July 14, 2016).</li><li><a class="nounderline abstract_t">Ornellas AA, Kinchin EW, Nóbrega BL, et al. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience. J Surg Oncol 2008; 97:487.</a></li><li><a class="nounderline abstract_t">Pettaway CA, Pagliaro L, Theodore C, Haas G. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology 2010; 76:S58.</a></li></ol></div><div id="topicVersionRevision">Topic 2959 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15610099" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Penile cancer in the UK: clinical presentation and outcome in 1998/99.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17855702" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Demographic and pathologic differences in the incidence of invasive penile cancer in the United States, 1995-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18980292" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16925747" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A prospective study of 100 cases of penile cancer managed according to European Association of Urology guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18986562" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epidemiologic study on penile cancer in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20691881" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Diagnosis and staging of penile cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14115903" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : EPIDERMOID CARCINOMA OF THE PENIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14352176" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Carcinoma of the penis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14492573" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cancer of the penis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4725734" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidermoid carcinoma of the penis: computer analysis of 87 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4801158" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Carcinoma of the penis. Experience with 153 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4801117" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Carcinoma of penis treated surgically. Analysis of 100 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4801117" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Carcinoma of penis treated surgically. Analysis of 100 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12175386" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Common skin disorders of the penis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17498438" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Angiokeratoma of the glans penis: clinical, histopathological and dermoscopic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8784283" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Squamous cell carcinoma of the penis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/852315" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cancer of the penis in Denmark 1942 to 1962 (511 cases).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/831359" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Condylomata acuminata and squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2544331" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Virology of human papillomavirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8380060" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : History of circumcision, medical conditions, and sexual activity and risk of penile cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35853783" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6259230" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cancers, precancers, and pseudocancers on the male genitalia. A review of clinical appearances, histopathology, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4757930" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Erythroplasia of Queyrat. A clinicopathologic and histochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10951274" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Erythroplasia of queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24313974" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : British Association of Dermatologists' guidelines for the management of squamous cell carcinoma in situ (Bowen's disease) 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6315601" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Human papillomavirus type-16-related DNA in genital Bowen's disease and in Bowenoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1574814" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Histopathology of malignant lesions of the penis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1736473" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Premalignant lesions and nonsquamous malignancy of the penis and carcinoma of the scrotum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2990353" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Bowenoid papulosis. Presence of human papillomavirus (HPV) structural antigens and of HPV 16-related DNA sequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3039749" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : [Transition to cutaneous squamous cell carcinoma in 2 patients with bowenoid papulomatosis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10971337" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Development of squamous cell carcinoma by two high-risk human papillomaviruses (HPVs), a novel HPV-67 and HPV-31 from bowenoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12786880" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Detection of human papillomavirus type 16 in bowenoid papulosis and nonbowenoid tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3002589" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bowenoid papulosis. A clinicopathologic study with ultrastructural observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1848870" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bowenoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1561268" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Squamous cell carcinoma and lichen sclerosus et atrophicus of the prepuce.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8349865" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Penile squamous cell carcinoma arising from balanitis xerotica obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16515998" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Penile carcinoma in patients with genital lichen sclerosus: a multicenter survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10971272" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The treatment of balanitis xerotica obliterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10570372" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Penile cancer among patients with genital lichen sclerosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4031162" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cutaneous horns of the penis: an approach to management. Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2172337" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cutaneous horn of the penis: its association with squamous cell carcinoma and HPV-16 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3603912" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Malignant evolution of penile horn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14488639" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Penile horn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6018427" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Penile horn: review of literature with 3 case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3967518" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pseudoepitheliomatous, keratotic, and micaceous balanitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3689682" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Is pseudoepitheliomatous, micaceous and keratotic balanitis synonymous with verrucous carcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2393789" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pseudo-epitheliomatous hyperkeratotic and micaceous balanitis: evidence for regarding it as pre-malignant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10886158" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Verrucous carcinoma arising in pseudoepitheliomatous keratotic and micaceous balanitis, without evidence of human papillomavirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10886158" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Verrucous carcinoma arising in pseudoepitheliomatous keratotic and micaceous balanitis, without evidence of human papillomavirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10886158" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Verrucous carcinoma arising in pseudoepitheliomatous keratotic and micaceous balanitis, without evidence of human papillomavirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31596650" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prognosis of the 8th TNM Staging System for Penile Cancer and Refinement of Prognostication by Incorporating High Risk Human Papillomavirus Status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18478188" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Local staging of penile cancer using magnetic resonance imaging with pharmacologically induced penile erection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20399455" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long-term followup of penile carcinoma with high risk for lymph node invasion treated with inguinal lymphadenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20691887" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prognostic factors in penile cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19477581" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20844435" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Therapeutic strategies for advanced penile carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15271324" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The role of lymphadenectomy in penile cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18440124" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16686716" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fine-needle aspiration cytology predicts inguinal lymph node metastasis without antibiotic pretreatment in penile carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705071" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Ultrasonography-guided fine-needle aspiration cytology before sentinel node biopsy in patients with penile carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35098622" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : High diagnostic accuracy of inguinal ultrasonography and fine-needle aspiration followed by dynamic sentinel lymph node biopsy in men with impalpable and palpable inguinal lymph nodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22088350" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Accuracy of sentinel lymph node biopsy for inguinal lymph node staging of penile squamous cell carcinoma: systematic review and meta-analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22088350" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Accuracy of sentinel lymph node biopsy for inguinal lymph node staging of penile squamous cell carcinoma: systematic review and meta-analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20800339" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prognostic factors for occult inguinal lymph node involvement in penile carcinoma and assessment of the high-risk EAU subgroup: a two-institution analysis of 342 clinically node-negative patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22928991" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Dynamic sentinel node biopsy in penile cancer: initial experiences at a Swedish referral centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18762945" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Contemporary inguinal lymph node dissection: minimizing complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35257463" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Incidence and risk factor analysis of complications after sentinel node biopsy for penile cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36906413" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23551693" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22901575" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Minimally invasive inguinal lymphadenectomy via endoscopic groin dissection: comprehensive assessment of immediate and long-term complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29307685" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Comparing Outcomes of Robotic and Open Inguinal Lymph Node Dissection in Patients with Carcinoma of the Penis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27628265" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Prospective study comparing video-endoscopic radical inguinal lymph node dissection (VEILND) with open radical ILND (OILND) for penile cancer over an 8-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239014" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Identification of high risk pathological node positive penile carcinoma: value of preoperative computerized tomography imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20723934" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Prognostic significance of extranodal extension in patients with pathological node positive penile carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20625118" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20625118" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18425779" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20691886" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
